Evolving role of FDG-PET-based global disease assessment and detection of response to nivolumab treatment in patients with non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Seraj, Siavash Mehdizadeh [2 ]
Jahangiri, Pegah [2 ]
Zadeh, Mahdi Zirakchian [1 ]
Kalboush, Eman [2 ]
Werner, Thomas [2 ]
Alavi, Abass [2 ]
Hunt, Stephen [2 ]
机构：
[1] Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2019年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1347
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Role of FDG-PET in disclosing RECIST-based pseudoprogression in non-small cell lung cancer (NSCLC) patients treated with Nivolumab
    Bauckneht, M.
    Rossi, G.
    Piva, R.
    Genova, C.
    Rijavec, E.
    Barletta, G.
    Biello, F.
    Ceriani, V.
    Calamia, I.
    Dal Bello, G.
    Di Stefano, R.
    Sambuceti, G.
    Grossi, F.
    Morbelli, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S333 - S333
  • [2] Patterns of Response to Nivolumab in Patients with Non-Small Cell Lung Cancer (NSCLC)
    Schmid, S.
    Diem, S.
    Krapf, M.
    Li, Q.
    Flatz, L.
    Leschka, S.
    Desbiolles, L.
    Klingbiel, D.
    Jochum, W.
    Fruh, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2419 - S2420
  • [3] The role of PET in radiotherapy treatment planning for patients with non-small cell lung cancer (NSCLC).
    Erdi, YE
    Yorke, ED
    Erdi, AK
    Hu, YC
    Braban, LE
    Macapinlac, H
    Humm, JL
    Squire, OD
    Larson, SM
    Chui, CS
    Rosenzweig, K
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 302P - 302P
  • [4] Role of 18F-FDG PET in Assessment of Response in Non-Small Cell Lung Cancer
    Hicks, Rodney J.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 : 31S - 42S
  • [5] FDG-PET response to nivolumab is predictive of tumor progression and survival in non-small cell lung cancer patients
    Seraj, Siavash Mehdizadeh
    Zadeh, Mandi Zirakchian
    Jahangiri, Pegah
    Kaghazchi, Fatemeh
    Kalboush, Eman
    Werner, Thomas
    Newberg, Andrew
    Hunt, Stephen
    Alavi, Abass
    Revheim, Mona-Elisabeth
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [6] Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
    Schmid, Sabine
    Diem, Stefan
    Li, Qiyu
    Krapf, Mirjam
    Flatz, Lukas
    Leschka, Sebastian
    Desbiolles, Lotus
    Klingbiel, Dirk
    Jochum, Wolfram
    Fruh, Martin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (12) : 1825 - 1832
  • [7] Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
    Sabine Schmid
    Stefan Diem
    Qiyu Li
    Mirjam Krapf
    Lukas Flatz
    Sebastian Leschka
    Lotus Desbiolles
    Dirk Klingbiel
    Wolfram Jochum
    Martin Früh
    Cancer Immunology, Immunotherapy, 2018, 67 : 1825 - 1832
  • [8] QUANTITATIVE ANALYSIS OF FDG PET/CT FOR ASSESSMENT OF THERAPY RESPONSE IN PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA TREATED WITH NIVOLUMAB
    Morigi, J. J.
    Rajadurai, S.
    Ferdinandus, J.
    Welch, J.
    Pathmaraj, K.
    Poon, A.
    Berlangieri, S.
    Lee, S. T.
    Scott, A. M.
    INTERNAL MEDICINE JOURNAL, 2019, 49 : 33 - 34
  • [9] Comparison of SUVmax and SUVpeak for response assessment in stage 4 non-small cell lung cancer (NSCLC) by FDG PET/CT
    Ong, Leonard
    Rager, Olivier
    Lohrmann, Christian
    Riedl, Christopher
    Pinker, Katja
    Weber, Wolfgang
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [10] Evaluation of the response for gefitinib in patients with non-small cell lung cancer (NSCLC) using FDG-PET scan.
    Fujishita, T
    Kashii, T
    Miwa, T
    Oda, H
    Kobayashi, M
    Nomura, K
    Seto, H
    Matsunari, I
    Hisada, KI
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 885S - 885S
12345